Viral Vector Upstream Platforms
Optimizing the upstream portion of gene therapy production sets the stage for successful manufacturing by maximizing viral vector titers. To increase upstream titers and process productivity, manufacturers must partner with upstream technology experts who work with HEK293, HEK293T and Sf9 cells. Draw on our experience today to speed your gene therapy to patients. Learn more.
See the answer from John Crowley, chairman and CEO at Amicus Therapeutics.
Krish and Suma Krishnan, the husband-and-wife team that founded and leads Krystal Biotech, cleared a path to market for the first ever topical and redosable gene therapy.
In the challenging development space for novel antibiotics, Spero Therapeutics is using partnership, external validation, and formulation science to develop drugs treating bacterial infections both rare and common.
The Promise Of AAV Gene Therapy With REGENXBIO's Ken Mills
Ken Mills, CEO, President, and Director at REGENXBIO joins Erin Harris for this episode of Cell & Gene: The Podcast to discuss the company's progress with its Phase I/II Affinity Duchenne trial of RGX-202 for the treatment of Duchenne Muscular Dystrophy. They discuss the future of AAV gene therapy as well as achieving scalability with consistent yield and product purity in gene therapy manufacturing. Listen now and subscribe so you never miss an episode!
CONTRIBUTE TO LIFE SCIENCE LEADER
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
|Connect With Life Science Leader:|